Abstract
Medical ProteoScope (MPS) is the company of proteomics excellence towards the better quality of life. In clinical practice, there is a need for biomarkers to help improve treatment outcomes. Based on integration of the state-ofthe-art proteomics technology, we have focused on development of protein biomarkers. Label-free comparative LC-MS/MS is our core analytical platform, associated with the self-made algorithms, i-OPAL and i-RUBY, for data alignment of non-linearly fluctuated LC elution time. Under quality control (QC) operations of these technologies, collaborative studies with academic institutions and drug companies led to identification of proteins related closely to drug response, current state of the disease, progression of the disease and metastatic risk in the case of cancer patients. Posttranslational modifications (PTMs) of proteins are the promising targets for understanding disease mechanisms. Since 2008, MPS participates in the coordination funds presided by Yokohama City University. We developed differential analysis systems of PTMs including reversible phosphorylation. Formalin-fixed paraffinembedded (FFPE) tissues archived in hospitals have a potential for discovery of the therapeutic targets as well as proteomic biomarkers. We have optimized protocols to dissect minute lesions from the FFPE tissues. Proteomic data of the collected specimens enabled to evaluate more accurately the disease state of the tissues. Thus, as a proteomics leading venture, MPS is continuously contributing to the fields of medicine.
